Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5741287 | 0.88 | LIMK1 (0.36) | LIMK1PRKCIBACE1BACE2 | |
| SCHEMBL5740852 | 0.86 | CYP11B2 (0.40) | PIK3CGCYP11B2CYP11B1LIMK1PRKCI | |
| SCHEMBL6502371 | 0.85 | PRMT5 (0.38) | PRMT5WDR77CYP2A6LIMK1PRKCI | |
| SCHEMBL5738937 | 0.85 | LIMK1 (0.40) | PIK3CGCYP11B2CYP11B1LIMK1BACE1 | |
| SCHEMBL5739106 | 0.83 | CYP11B2 (0.43) | PIK3CGPRMT5WDR77CYP2A6CYP11B2 | |
| SCHEMBL5738867 | 0.82 | ABL1 (0.40) | PRMT5WDR77CYP11B2CYP11B1 | |
| SCHEMBL5741185 | 0.80 | PIK3CG (0.42) | PIK3CGCYP2A6LIMK1 | |
| SCHEMBL5740728 | 0.78 | ABL1 (0.41) | CYP2A6CYP11B2LIMK1PRKCICYP1A2 | |
| SCHEMBL5738998 | 0.77 | LIMK1 (0.34) | LIMK1 | |
| SCHEMBL5740480 | 0.76 | KIF11 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406891-B1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | BAYER HEALTHCARE AG (DE) | 2005-01-13 | — | — | US | disclosed |
| EP-1406891-A1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | Bayer HealthCare AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003053955-A1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | HTT, HMOX1, SNCA | PIK3CG 4431/4885PRMT5 3297/4885WDR77 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.